Ocena ekspresji receptora estrogenowego, progesteronowego i receptora HER2 w wybranych nowotworach złośliwych ślinianek
Journal Title: Otolaryngologia Polska - Year 2013, Vol 67, Issue 5
Abstract
Introduction: The incidence of the malignant tumors of the salivary glands is relatelively low. However, rapid locoregional progression, distant metastases occurrence and high local recurrence rate occurring despite radical surgical treatment, significantly affect the outcome. Malignant tumors of the salivary glands are characterized by low radiosensitivity and poor response to systemic therapy. Therefore there is a need for new targeted therapies which may improve the prognosis. In some aspects, malignant tumors of the salivary glands are similar to breast cancers. Efficacy of hormonal replacement therapy and the treatment with the monoclonal antibody (trastuzumab) in the treatment of breast cancer is well known and confirmed. Criterion determining the qualification for treatment is the presence of hormone receptors and HER2 receptors in the tumor. Aim: The aim of this study was to evaluate the expression of estrogen receptor, progesterone receptor and HER2 in selected salivary gland malignancies. Materials and methods: Study group consisted of 51 patients with the salivary glands cancer. In the study group there were 42 tumors in the parotid gland, 7 tumors of the submandibular gland, 1 in the mucosa of the cheek and 1 tumor in the tongue. Histologically material comprised of muco-epidermoid carcinoma (10), adenoid-cystic carcinoma (8), salivary duct (7), adenocarcinoma (6), squamous cell carcinoma (6), mioepithelial carcinoma (5) and other (9). In all cases immunohistochemical analysis of the estrogen receptor, progesterone receptor and HER2 receptor was performed. Results: The expression of the estrogen receptor was found in 18% of tumors (9 patients). The expression of the progesterone receptor was found in 20% (10 patients). HER2 expression was found in 10% of tumors and was related to only one histological type of tumor – salivary duct carcinoma. Conclusion: HER2 expression in malignant tumors of the salivary glands, especially in salivary duct carcinoma may be of use in future implementation of new targeted therapies based on monoclonal antibodies.
Authors and Affiliations
Wojciech Golusiński, Anna Wegner, Paweł Trzeciak, Marcin Sówka, Andrzej Kopczyński, Małgorzata Bromboszcz
Keywords
Related Articles
- EP ID EP52211
- DOI -
- Views 120
- Downloads 0
Controversial role of bisphosphonates in osteonecrosis of the jaws
Aim of the study: Evaluation of the role of bisphosphonates in jaw osteonecrosis. Material and methods: A retrospective cohort study on 29 patients. The bisphosphonate group consisted of 12 multiple myelomas, 3 breast ca...
A new approach to studying the nasal and oral breathing routes
Introduction: Nasal obstruction is often reported by patients. It is a consequence of a subjective feeling of impaired airflow through the nasal cavity. Currently, objective measures of nasal patency rates are very limit...
Sprawozdanie z XXI Sympozjum Międzynarodowej Grupy Badawczej Audiometrii Odpowiedzi Wywołanych (IERASG) w Rio de Janeiro, 8-11 czerwca 2009
Trudności diagnostyczne i terapeutyczne inwazyjnej grzybicy zatok przynosowych o piorunującym przebiegu
The autors present the diagnostic and therapeutical diffi culties of acute (fulminant) invasive mycotic rhinosinusitis. A case report of mycotic rhinosinusogenes meningitis in 50 years old woman is described in this pape...
Angifibroma juvenile — evolution of surgical management
SUMMARY Introduction: Juvenile Angiofibroma has been challenged generations of surgeons. The problem is, not only in specific clinical features of the tumour, but also in difficult surgical approach to anatomical area in...